Compare Quest Diagnostics Inc (DGX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PepsiCo, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while PepsiCo, Inc. trades at $135.8 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 8.1× Quest Diagnostics Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| DGX | PEP | |
|---|---|---|
Market Cap | $22.80B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $170.44 |
52-Week Low | $166.42 | $133.81 |
Enterprise Value | $28.82B | $227.37B |
Dividend Yield | 1.67% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PepsiCo (PEP) trades at $138.49, up 0.81% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and consistent earnings growth potential, though near-term technical weakness and pricing strategy adjustments present headwinds. The stock trades at reasonable valuation multiples (P/E 17.75) with upside to analyst targets, but investors should monitor North American performance recovery and consumer pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
